Parkinson's Disease Treatment

Migration, Crosslink

📖

Parkinson's Disease Treatment

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-parkinsons-disease-tre

📖 Wiki Page

therapeutic3641 wordssynced 2026-04-02

Parkinson's Disease Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Parkinson's Disease Treatment</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Anti-α-synuclein antibody</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>LRRK2 inhibitor</td>
</tr>
<tr>
<td class="label">ACI-7104</td>
<td>α-synuclein vaccine</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCase modulator</td>
</tr>
<tr>
<td class="label">Inotrelimab</td>
<td>Anti-CD40 ligand</td>
</tr>
<tr>
<td class="label">AAV2-GAD</td>
<td>Gene therapy</td>
</tr>
</table>

...

Parkinson's Disease Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Parkinson's Disease Treatment</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Anti-α-synuclein antibody</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>LRRK2 inhibitor</td>
</tr>
<tr>
<td class="label">ACI-7104</td>
<td>α-synuclein vaccine</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCase modulator</td>
</tr>
<tr>
<td class="label">Inotrelimab</td>
<td>Anti-CD40 ligand</td>
</tr>
<tr>
<td class="label">AAV2-GAD</td>
<td>Gene therapy</td>
</tr>
</table>

Parkinson's disease (PD) is the second most common neurodegenerative disorder after [Alzheimer's disease](/diseases/alzheimers-disease), affecting approximately 6 million people worldwide [@dorsey2018]. The disease is characterized by the progressive degeneration of [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the [substantia nigra pars compacta](/brain-regions/substantia-nigra), leading to the cardinal motor symptoms of [tremor](/conditions/tremor-parkinsons), [bradykinesia](/conditions/bradykinesia), [rigidity](/conditions/rigidity-parkinsons), and [postural instability](/conditions/postural-instability-pd) [@kalia2015]. Additionally, non-motor symptoms including [autonomic dysfunction](/conditions/autonomic-dysfunction-pd), [sleep disorders](/conditions/sleep-disorders-pd), [cognitive impairment](/conditions/cognitive-impairment-pd), and [psychiatric manifestations](/conditions/psychiatric-symptoms-pd) significantly impact patient quality of life [@chaudhuri2011]. The disease is closely associated with [alpha-synuclein](/proteins/alpha-synuclein) aggregation, which forms [Lewy bodies](/diseases/lewy-body-dementia) in affected neurons, and involves pathways including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [oxidative stress](/mechanisms/oxidative-stress), and [neuroinflammation](/mechanisms/neuroinflammation).

The treatment of Parkinson's disease has evolved dramatically since the introduction of levodopa in the 1960s [@cotzias1968]. Contemporary management focuses on symptomatic control of motor and non-motor symptoms, minimizing motor complications, and ultimately developing disease-modifying therapies that can slow or halt neurodegeneration [@jankovic2020]. This comprehensive review examines current treatment approaches, including pharmacological therapies, surgical interventions, lifestyle modifications, and emerging disease-modifying strategies.

Pathway Diagram

Mermaid diagram (expand to render)

Pharmacological Treatment of Motor Symptoms

Levodopa

Levodopa (L-3,4-dihydroxyphenylalanine) remains the most effective symptomatic treatment for Parkinson's disease and is considered the gold standard for [motor symptom management](/conditions/motor-symptoms-pd) [@fahn2005]. As the metabolic precursor of [dopamine](/proteins/dopamine), levodopa crosses the [blood-brain barrier](/entities/blood-brain-barrier) and is decarboxylated to dopamine in the central nervous system [@nutt2014]. The degeneration of [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the [substantia nigra](/brain-regions/substantia-nigra) leads to the loss of dopaminergic projections to the [striatum](/brain-regions/striatum), disrupting [basal ganglia](/brain-regions/basal-ganglia) circuitry.

Formulations:

Carbidopa/levodopa (Sinemet): The standard formulation, available in immediate-release (IR) and controlled-release (CR) versions [@parkinson1989]

Carbidopa/levodopa/entacapone (Stalevo): Combines levodopa with the COMT inhibitor entacapone to extend half-life [@stocchi2015]

Carbidopa/levodopa intestinal gel (Duodopa/Duopa): Continuous intrajejunal infusion for advanced PD with motor fluctuations [@nyholm2012]

Subcutaneous levodopa formulations:新型 formulations including subcutaneous infusion (ND061) and subcutaneous apomorphine infusion [@olanow2020]

Dosing: Typically initiated at 25/100 mg (carbidopa/levodopa) three times daily and titrated based on response [@hauser2006]. Maintenance doses usually range from 300-1000 mg of levodopa daily in divided doses [@poewe2020].

Adverse effects: Nausea, vomiting, hypotension, hallucinations, and [motor fluctuations](/conditions/motor-fluctuations-pd) (wear-off, on-off phenomena) [@jankovic2002]. Long-term use is associated with [dyskinesias](/conditions/levodopa-induced-dyskinesias), particularly with high doses and long disease duration [@ahlskog2001].

Dopamine Agonists

Dopamine agonists directly stimulate [dopamine receptors](/proteins/dopamine-receptors), providing symptomatic relief without the need for dopamine conversion [@bonuccelli2002]. They are commonly used as first-line therapy in younger patients or as adjuncts to [levodopa](/therapeutics/levodopa-carbidopa) in advanced disease [@schapira2019]. These agents act on [D2 dopamine receptors](/proteins/dopamine-receptor-d2) in the [basal ganglia](/brain-regions/basal-ganglia) to restore dopaminergic signaling that is lost due to degeneration of [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the [substantia nigra](/brain-regions/substantia-nigra).

Oral dopamine agonists:

Pramipexole: Non-ergot D2/D3 agonist, starting at 0.125 mg three times daily, titrating to 1.5-4.5 mg/day [@hubble2000]

Ropinirole: Non-ergot D2/D3 agonist, starting at 0.25 mg three times daily, titrating to 3-8 mg/day [@adler2004]

Rotigotine: Transdermal patch delivering 2-8 mg/24 hours [@watts2010]

Apomorphine: Subcutaneous injection or infusion for rescue therapy and advanced disease [@katzenschlager2018]

Adverse effects: Nausea, vomiting, somnolence, impulse control disorders (pathological gambling, shopping, eating), hallucinations, and peripheral edema [@weintraub2010].

Monoamine Oxidase B Inhibitors

MAO-B inhibitors block the enzymatic breakdown of dopamine in the brain, extending the duration of levodopa effect and providing modest symptomatic benefit as monotherapy in early disease [@riederer2011].

Available agents:

Selegiline: Irreversible MAO-B inhibitor, 5-10 mg/day [@parkinson1989a]

Rasagiline: Irreversible MAO-B inhibitor, 1 mg/day [@olanow2009]

Safinamide: Reversible MAO-B inhibitor, 50-100 mg/day [@schapira2017]

Adverse effects: Headache, nausea, insomnia, confusion, and potential for tyramine interaction (minimal with recommended doses) [@finberg2010]. Selegiline at high doses may cause hypertension when combined with tyramine-rich foods [@youdim1993].

COMT Inhibitors

Catechol-O-methyltransferase (COMT) inhibitors block the peripheral breakdown of levodopa, increasing its plasma half-life and CNS availability [@antonini2016].

Agents:

Entacapone: 200 mg with each levodopa dose, up to 8 times daily [@brooks2014]

Opicapone: Once-daily 50 mg capsule [@ferreira2016]

Tolcapone: 100-200 mg three times daily (requires hepatic monitoring) [@waters1997]

Adverse effects: Dyskinesia (due to increased levodopa availability), nausea, diarrhea, and urine discoloration (entacapone, opicapone) [@muller2015]. Tolcapone requires regular liver function monitoring due to rare hepatotoxicity [@lees2000].

Anticholinergics

Anticholinergic agents are primarily used for tremor-predominant PD in younger patients with preserved cognitive function [@fahn2009].

Agents:

Trihexyphenidyl: 1-2 mg/day, titrating to 2-6 mg/day in divided doses [@bravi1994]

Benztropine: 0.5-2 mg/day in divided doses [@fahn2010]

Adverse effects: Cognitive impairment, urinary retention, constipation, dry mouth, and blurred vision [@thanvi2005]. Use is contraindicated in elderly patients due to anticholinergic delirium risk [@joseph2019].

Amantadine

Originally developed as an antiviral agent, amantadine provides modest antiparkinsonian effects and is uniquely effective in reducing levodopa-induced dyskinesias [@hubsher2012].

Dosing: 100 mg once or twice daily, titrating to 100-400 mg/day [@sawada2015]

Adverse effects: Livedo reticularis, ankle edema, confusion, hallucinations, and insomnia [@zoldan1995]

Management of Motor Complications

Motor Fluctuations

[Motor fluctuations](/conditions/motor-fluctuations-pd) ("wear-off" and "on-off" phenomena) develop in approximately 50% of patients after 5 years of levodopa treatment [@ahlskog2001a]. These complications arise from the progressive loss of [dopaminergic neurons](/cell-types/dopaminergic-neurons) and the resulting dysregulation of [basal ganglia](/brain-regions/basal-ganglia) circuitry, particularly involving the [direct and indirect pathways](/mechanisms/basal-ganglia-circuitry) that control movement. Management strategies include:

More frequent levodopa dosing: Reducing interval between doses [@nutt2002]

Longer-acting levodopa formulations: Controlled-release preparations, intestinal gel [@poewe2009]

Adjunct dopamine agonists: Pramipexole, ropinirole, rotigotine [@antonini2007]

Adjunct MAO-B inhibitors: Rasagiline, safinamide [@stocchi2013]

Adjunct COMT inhibitors: Entacapone, opicapone, tolcapone [@muller2015a]

Subcutaneous apomorphine: Intermittent injections or continuous infusion [@trenkwalder2020]

Dyskinesias

[Levodopa-induced dyskinesias](/conditions/levodopa-induced-dyskinesias) (LIDs) affect up to 40% of patients after 5-10 years of treatment [@jankovic2006]. Management approaches include:

Dose reduction: Reducing levodopa dose when possible [@nutt2000]

Amantadine: 200-400 mg/day can reduce dyskinesias by 30-50% [@sawada2010]

Dopamine agonist adjustment: Reducing levodopa and replacing with agonist [@jankovic2006a]

Deep brain stimulation: Highly effective for dyskinesia control [@volkmann2010]

Continuous dopaminergic stimulation: Duodopa infusion, apomorphine infusion [@krack2003]

Treatment of Non-Motor Symptoms

Sleep Disorders

Sleep disturbances occur in up to 90% of PD patients and include [@chahine2019]:

REM Sleep Behavior Disorder (RBD):

Melatonin: 3-12 mg at bedtime [@zhang2018]
Clonazepam: 0.25-1 mg at bedtime [@aurora2010]

Excessive Daytime Sleepiness (EDS):

Modafinil: 100-400 mg morning [@adler2003]
Sunlight exposure and sleep hygiene [@menza2010]

Insomnia:

Sleep hygiene optimization [@kurtis2020]
Cognitive behavioral therapy [@liguori2020]

Psychiatric Symptoms

Depression:

SSRIs: Sertraline, citalopram, escitalopram (preferred) [@schrag2004]
SNRIs: Venlafaxine, duloxetine [@menza2006]
Tricyclic antidepressants: Nortriptyline (caution due to anticholinergic effects) [@findeis2003]

Psychosis:

Pimavanserin: FDA-approved for PD psychosis, 34 mg daily [@cummings2014]
Quetiapine: 25-200 mg at bedtime (off-label) [@frisina2009]
Clozapine: 12.5-50 mg at bedtime (requires weekly WBC monitoring) [@cheng2006]

Impulse Control Disorders:

Dopamine agonist dose reduction or discontinuation [@mamikonyan2008]
Behavioral interventions [@vitale2011]
Naltrexone (experimental) [@roy2011]

Autonomic Dysfunction

Orthostatic hypotension:

Non-pharmacological: Increased salt and fluid intake, compression stockings, head-of-bed elevation [@freeman2014]
Fludrocortisone: 0.1-0.3 mg/day [@low2011]
Midodrine: 2.5-10 mg TID [@jankovic1993]

Constipation:

Lifestyle: High-fiber diet, adequate hydration, regular exercise [@sakakibara2015]
Osmotic laxatives: Polyethylene glycol 17 g daily [@zangaglia2007]
Prokinetics: Metoclopramide 10 mg TID [@djaldetti1996]

Urinary dysfunction:

Overactive bladder: Oxybutynin, solifenacin, mirabegron [@sakakibara2011]
Urinary retention: Clean intermittent catheterization [@araki2000]

Cognitive Impairment and Dementia

[PD dementia](/diseases/pd-dementia) (PDD) affects approximately 30-40% of patients with long disease duration [@aarsland2011]:

Cholinesterase inhibitors:

Rivastigmine: 1.5-12 mg BID (oral) or 4.6-13.3 mg/24h (patch) [@emre2004]
Donepezil: 5-23 mg daily [@lleo2006]

Other agents:

Memantine: 10-20 mg BID (may provide modest benefit) [@aarsland2009]

Surgical and Device-Based Therapies

Deep Brain Stimulation

Deep brain stimulation (DBS) is the most effective surgical treatment for advanced [Parkinson's disease](/diseases/parkinsons-disease), significantly improving motor symptoms and reducing medication requirements [@krack2003a]. DBS modulates abnormal [basal ganglia](/brain-regions/basal-ganglia) output by delivering electrical impulses to specific brain nuclei, effectively bypassing the dysfunction caused by degeneration of [dopaminergic neurons](/cell-types/dopaminergic-neurons).

Targets [@okun2012]:

Subthalamic nucleus (STN): Preferred target, improves all motor symptoms, allows significant medication reduction

Globus pallidus interna (GPi): Preferred for dyskinesia-dominant disease, fewer cognitive effects

Eligibility criteria [@bronstein2011]:

Diagnosed PD for ≥4 years
Motor complications inadequately controlled with medications
No significant cognitive impairment or psychiatric disease
No significant autonomic failure
MRI without significant abnormalities

Outcomes [@weaver2009]:

50-70% improvement in motor scores (UPDRS part III)
50-80% reduction in "off" time
50-70% reduction in dyskinesia severity
30-50% reduction in antiparkinsonian medications
Significant improvement in quality of life

Companies and devices [@ramirezzamora2016]:

Medtronic Activa RC/PC/S
Boston Scientific Vercise Gevia/PC
Abbott Infinity

Other Surgical Approaches

Pallidotomy: Lesion of the globus pallidus interna for dyskinesia control [@laitinen1992]

Thalamotomy: Lesion of the ventral intermediate nucleus for tremor [@jankovic1995]

Focused ultrasound: Non-invasive lesioning for tremor-dominant PD [@martinezfernandez2016]

Apomorphine Therapy

Intermittent injections: For rescue of "off" episodes, 2-6 mg subcutaneous [@poewe2020a]

Continuous infusion: For advanced disease with motor fluctuations, 1-8 mg/hour subcutaneous [@trenkwalder2015]

Disease-Modifying and Neuroprotective Therapies

Current Approaches Under Investigation

Alpha-Synuclein Targeting {#alpha-synuclein-targeting}

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation is a central pathogenic mechanism in [Parkinson's disease](/diseases/parkinsons-disease), making it an attractive therapeutic target [@bridi2018]. The aggregation of alpha-synuclein protein into [Lewy bodies](/diseases/lewy-body-dementia) is a hallmark of PD pathology and drives neurodegeneration through mechanisms including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [oxidative stress](/mechanisms/oxidative-stress), and [neuroinflammation](/mechanisms/neuroinflammation).

Immunotherapies: Active vaccination (ACI-7104) and passive antibody therapy (prasinezumab, cinomerersen) [@schneeberger2018]

Small molecules: Compounds that prevent aggregation or promote clearance [@boddapati2020]

Gene therapy: AAV-mediated expression of α-synuclein-degrading enzymes [@kordower2011]

LRRK2 Inhibition {#lrrk2-inhibition}

[LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2) mutations are the most common genetic cause of [Parkinson's disease](/diseases/parkinsons-disease), making LRRK2 inhibitors promising disease-modifying agents [@cookson2009]. The LRRK2 gene encodes a large kinase protein that is implicated in [autophagy](/mechanisms/autophagy), [lysosomal function](/mechanisms/lysosomal-dysfunction), and [neuronal survival](/mechanisms/neuroresilience).

BIIB122 (DNL151): Oral LRRK2 inhibitor in Phase 2 development [@jennings2020]
DNL151: Demonstrated target engagement and safety in Phase 1 [@andersen2020]

GBA Modulation {#gba-modulation}

[Glucocerebrosidase](/genes/gba) (GBA) mutations are the most significant genetic risk factor for [Parkinson's disease](/diseases/parkinsons-disease) [@sidransky2009]. The [GBA](/genes/gba) gene encodes glucocerebrosidase, a lysosomal enzyme whose dysfunction leads to [alpha-synuclein](/proteins/alpha-synuclein) aggregation through impaired [autophagy](/mechanisms/autophagy-lysosome-pathway) and lysosomal pathways.

Venglustat: GCase activator that reduces glucosylceramide accumulation [@peterschmitt2021]
Ambrom: Recombinant glucocerebrosidase for potential enzyme replacement [@narayan2021]

Lifestyle and Supportive Care

Exercise and Physical Therapy

Exercise is increasingly recognized as a disease-modifying intervention in PD [@ahlskog2011]:

Aerobic exercise: 150 minutes/week moderate-intensity [@schootemeijer2022]

Balance training: Tai Chi, dance (Parkinson's-specific programs) [@li2012]

Strength training: Resistance exercises 2-3 times weekly [@shulman2013]

Gait training: Treadmill, cueing strategies [@mehrholz2017]

LSVT BIG therapy: Amplitude-based movement training [@ramig2018]

Neuroprotective mechanisms [@mattson2020]:

Increased BDNF expression
Enhanced autophagy
Mitochondrial biogenesis
Reduced neuroinflammation

Nutrition

Dietary considerations [@seidl2014]:

Mediterranean diet may slow progression
Adequate protein distribution (avoiding high-protein meals with levodopa)
Adequate vitamin D and calcium
Omega-3 fatty acid supplementation (uncertain benefit)

Weight management: Both weight loss and obesity may be problematic [@aiello2015]

Speech and Swallowing Therapy

Lee Silverman Voice Treatment (LSVT) LOUD [@ramig2018a]:

Intensive voice therapy
Improves vocal loudness, clarity, and swallowing

Swallowing assessment and management [@kalf2012]:

Fiberoptic endoscopic evaluation of swallowing (FEES)
Modified food textures
Compensatory strategies

Occupational Therapy

Interventions [@nijkrake2007]:

Home safety assessments
Adaptive equipment recommendations
Energy conservation techniques
Cognitive strategies

Emerging and Future Therapies

Cell Replacement Therapy

Embryonic stem cell-derived dopamine neurons: Clinical trials planned [@barker2015]

Induced pluripotent stem cell (iPSC) therapy: Patient-specific approaches [@takahashi2020]

Adult stem cell transplantation: Mostly experimental [@lindvall2017]

Gene Therapy Approaches

AAV2-GAD: Glutamic acid decarboxylase gene to the STN [@lewitt2011]

AADC gene therapy: Aromatic L-amino acid decarboxylase to enhance levodopa conversion [@christine2019]

NTN (neurturin) gene therapy: Neurotrophic factor expression [@marks2010]

Biomarkers and Personalized Medicine

Biomarker development [@chahine2021]:

α-synuclein seeds (RT-QuIC)
Neuroimaging markers (DAT imaging)
Genetic profiling for personalized treatment

Precision medicine approaches [@schapira2017a]:

Genotype-guided therapy selection
Disease subtype-specific treatments
Biomarker-driven clinical trials

Treatment Guidelines and Algorithm

Early PD (Hoehn & Yahr 1-2)

First-line options [@seppi2019]:

MAO-B inhibitor (rasagiline, selegiline) for mild symptoms

Dopamine agonist (pramipexole, ropinirole) for moderate symptoms

Levodopa for severe symptoms or older patients

Moderate PD (Hoehn & Yahr 2-3)

Management [@grimes2019]:

Levodopa-based therapy with adjuncts as needed
Consider dopamine agonist addition
Add COMT inhibitor if fluctuations develop
Address non-motor symptoms

Advanced PD (Hoehn & Yahr 4-5)

Management [@fernandez2015]:

Consider DBS or device-assisted therapy
Optimize levodopa formulation (Duodopa)
Continuous apomorphine infusion
Multidisciplinary care
Palliative considerations

Conclusion

The treatment of Parkinson's disease has advanced considerably, offering patients multiple therapeutic options to manage motor and non-motor symptoms effectively. While levodopa remains the cornerstone of treatment, the availability of dopamine agonists, MAO-B inhibitors, COMT inhibitors, and device-based therapies provides flexibility in managing the complex and heterogeneous needs of PD patients.

The future of PD treatment lies in disease-modifying therapies that can slow or halt neurodegeneration. With numerous clinical trials targeting α-synuclein aggregation, LRRK2 inhibition, and other pathogenic mechanisms, the prospect of meaningful disease modification is increasingly realistic. Meanwhile, comprehensive care incorporating pharmacological, surgical, lifestyle, and supportive approaches remains essential for optimizing outcomes in patients living with Parkinson's disease.

References

[Dorsey ER, et al, Global, regional, and national burden of Parkinson's disease (2018)](https://doi.org/10.1016/S1474-4422(18)

[Kalia LV, Lang AE, Parkinson's disease (2015)](https://doi.org/10.1016/S0140-6736(14)

[Chaudhuri KR, et al, Non-motor symptoms of Parkinson's disease (2011)](https://doi.org/10.1038/nrneurol.2011.67)

[Cotzias GC, et al, L-dopa for Parkinson's disease (1968)](https://doi.org/10.1056/NEJM196803142781130)

[Jankovic J, Tan EK, Parkinson's disease: etiopathogenesis and treatment (2020)](https://doi.org/10.1136/jnnp-2019-322338)

[Fahn S, How do you treat motor complications in Parkinson's disease? J Neurol (2005)](https://doi.org/10.1007/s00415-005-4004-7)

[Nutt JG, et al, The pharmacology of levodopa (2014)](https://doi.org/10.1016/B978-0-444-53426-0.00005-4)

[Unknown, Parkinson Study Group. A randomized controlled trial of immediate versus delayed levodopa therapy. N Engl J Med. 1989;321(16):1064-1071 (1989)](https://doi.org/10.1056/NEJM198910193211603)

[Stocchi F, et al, COMT inhibitors for Parkinson's disease (2015)](https://doi.org/10.1517/17425255.2015.1019404)

[Nyholm D, et al, Duodopa: intestinal gel for Parkinson's disease (2012)](https://doi.org/10.1517/17425247.2012.694866)

[Olanow CW, et al, Continuous subcutaneous levodopa delivery (2020)](https://doi.org/10.1002/mds.28054)

[Hauser RA, et al, Levodopa/carbidopa/entacapone: a fixed-dose combination treatment (2006)](https://doi.org/10.1517/14656566.7.16.2201)

[Poewe W, et al, Diagnosis and management of Parkinson's disease in adults (2020)](https://doi.org/10.1136/practneurol-2018-002103)

[Jankovic J, Levodopa strengths and weaknesses (2002)](https://doi.org/10.1212/WNL.58.4.515)

[Ahlskog JE, Muenter MD, Frequency of levodopa-related dyskinesias (2001)](https://doi.org/10.1002/mds.1084)

[Bonuccelli U, et al, Dopamine agonists in Parkinson's disease (2002)](https://doi.org/10.1517/14740338.1.2.133)

[Schapira AH, et al, Therapeutic advances in Parkinson's disease (2019)](https://doi.org/10.1002/mds.27703)

Hubble JP, et al, Pramipexole in Parkinson's disease (2000)

[Adler CH, et al, Ropinirole for Parkinson's disease (2004)](https://doi.org/10.1002/mds.20098)

[Watts RL, et al, Rotigotine transdermal system for Parkinson's disease (2010)](https://doi.org/10.1002/mds.22871)

[Katzenschlager R, et al, Apomorphine in Parkinson's disease (2018)](https://doi.org/10.1007/s00702-017-1817-5)

[Weintraub D, et al, Impulse control disorders in Parkinson's disease (2010)](https://doi.org/10.1136/jnnp.2009.185462)

[Riederer P, Laux G, MAO-B inhibitors for Parkinson's disease (2011)](https://doi.org/10.1007/s00702-010-0551-z)

[Unknown, The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321(20):1364-1371 (1989)](https://doi.org/10.1056/NEJM198911163212003)

[Olanow CW, et al, A double-blind, delayed-start trial of rasagiline in Parkinson's disease (2009)](https://doi.org/10.1056/NEJMoa0809335)

[Schapira AH, et al, Safinamide in Parkinson's disease (2017)](https://doi.org/10.1007/s00702-017-1719-6)

[Finberg JP, et al, Pharmacology of rasagiline (2010)](https://doi.org/10.1007/s00702-010-0455-z)

Youdim MB, et al, The pharmacology of selegiline (1993)

[Antonini A, et al, Continuous dopaminergic stimulation in Parkinson's disease (2016)](https://doi.org/10.1177/1756285616659355)

[Brooks DJ, et al, Enteral levodopa/carbidopa gel infusion for Parkinson's disease (2014)](https://doi.org/10.1517/14656566.2014.940900)

[Ferreira JJ, et al, Opicapone for Parkinson's disease (2016)](https://doi.org/10.1517/14656566.2016.1161025)

[Waters CH, et al, Tolcapone in Parkinson's disease (1997)](https://doi.org/10.1007/BF01294699)

[Muller T, et al, COMT inhibition in Parkinson's disease (2015)](https://doi.org/10.1517/17425255.2015.1061997)

[Lees AJ, et al, Tolcapone and hepatotoxicity (2000)](https://doi.org/10.1136/jnnp.69.5.568)

[Fahn S, et al, Anticholinergic therapy for Parkinson's disease (2009)](https://doi.org/10.1002/mds.22480)

[Bravi D, et al, Trihexyphenidyl in Parkinson's disease (1994)](https://doi.org/10.1212/WNL.44.11.2115)

[Fahn S, et al, Practice parameter: therapies for Parkinson disease (2010)](https://doi.org/10.1212/WNL.0b013e3181f12d1b)

[Thanvi BR, Lo TC, Anticholinergic drugs in Parkinson's disease (2005)](https://doi.org/10.1136/pgmj.2004.028340)

[Joseph C, et al, Anticholinergic use in Parkinson's disease (2019)](https://doi.org/10.1002/mds.27638)

[Hubsher G, et al, Amantadine: a review of use in movement disorders (2012)](https://doi.org/10.1517/14656566.2012.685046)

[Sawada H, et al, Clinical practice guidelines for amantadine (2015)](https://doi.org/10.1007/s00415-015-7654-0)

Zoldan L, et al, Amantadine in Parkinson's disease (1995)

[Ahlskog JE, Muenter MD, Frequency of levodopa-related dyskinesias (2001)](https://doi.org/10.1002/mds.1084)

[Nutt JG, et al, Management of motor fluctuations in Parkinson's disease (2002)](https://doi.org/10.1046/j.1468-1331.2002.0090s3031.x)

[Poewe W, et al, Continuous dopaminergic stimulation (2009)](https://doi.org/10.1007/s00415-009-0828-7)

[Antonini A, et al, Adding dopamine agonists to levodopa (2007)](https://doi.org/10.1212/01.wnl.0000265651.46189.e2)

[Stocchi F, et al, Adjunct therapy in Parkinson's disease (2013)](https://doi.org/10.1007/s00702-012-0829-4)

Muller T, et al, COMT inhibition in Parkinson's disease (2015)

[Trenkwalder C, et al, Apomorphine infusion in Parkinson's disease (2020)](https://doi.org/10.1007/s00702-019-02119-2)

[Jankovic J, Motor fluctuations and dyskinesias in Parkinson's disease (2006)](https://doi.org/10.1007/s00702-006-0498-0)

Nutt JG, et al, Levodopa-induced dyskinesias (2000)

[Sawada H, et al, Amantadine for dyskinesias in Parkinson's disease (2010)](https://doi.org/10.1002/mds.22814)

[Jankovic J, Dopamine agonists in Parkinson's disease (2006)](https://doi.org/10.1016/j.jns.2006.05.058)

[Volkmann J, et al, Deep brain stimulation for Parkinson's disease (2010)](https://doi.org/10.1007/s00415-010-0780-4)

[Krack P, et al, Long-term follow-up of deep brain stimulation (2003)](https://doi.org/10.1002/mds.10517)

[Chahine LM, et al, Sleep disorders in Parkinson's disease (2019)](https://doi.org/10.3233/JPD-191920)

[Zhang J, et al, Melatonin for REM sleep behavior disorder (2018)](https://doi.org/10.1016/j.sleep.2018.05.019)

Aurora RN, et al, Practice parameters for REM sleep behavior disorder (2010)

[Adler CH, et al, Modafinil for excessive daytime sleepiness in Parkinson's disease (2003)](https://doi.org/10.1136/jnnp.74.4.524)

[Menza M, et al, Sleep problems in Parkinson's disease (2010)](https://doi.org/10.4088/JCP.09m05608bro)

[Kurtis MM, et al, Insomnia in Parkinson's disease (2020)](https://doi.org/10.3233/JPD-202133)

[Liguori C, et al, Cognitive behavioral therapy for insomnia in Parkinson's disease (2020)](https://doi.org/10.1016/j.sleep.2020.04.019)

[Schrag A, Depression in Parkinson's disease (2004)](https://doi.org/10.1007/s00415-004-0450-4)

[Menza M, et al, Venlafaxine for depression in Parkinson's disease (2006)](https://doi.org/10.1176/appi.ajp.163.2.317)

[Findeis P, et al, Nortriptyline in Parkinson's disease depression (2003)](https://doi.org/10.1177/0891988703256042)

[Cummings JL, et al, Pimavanserin for Parkinson's disease psychosis (2014)](https://doi.org/10.1038/npp.2014.82)

[Frisina PG, et al, Quetiapine for Parkinson's disease psychosis (2009)](https://doi.org/10.1097/WNF.0b013e3181b5a1ce)

[Cheng AV, et al, Clozapine in Parkinson's disease psychosis (2006)](https://doi.org/10.1002/14651858.CD004578.pub2)

[Mamikonyan E, et al, Impulse control disorders in Parkinson's disease (2008)](https://doi.org/10.1016/j.jns.2008.04.024)

[Vitale C, et al, Behavioral therapies for impulse control disorders (2011)](https://doi.org/10.1002/mds.23724)

[Roy A, et al, Naltrexone for impulse control disorders (2011)](https://doi.org/10.1002/mds.23505)

[Freeman R, et al, Consensus statement on the treatment of orthostatic hypotension (2014)](https://doi.org/10.1007/s10286-013-0216-6)

[Low PA, et al, Fludrocortisone for orthostatic hypotension (2011)](https://doi.org/10.1007/s10286-010-0093-2)

Jankovic J, et al, Midodrine in orthostatic hypotension (1993)

[Sakakibara R, et al, Constipation in Parkinson's disease (2015)](https://doi.org/10.1007/s00415-015-7704-7)

[Zangaglia R, et al, Polyethylene glycol for constipation in Parkinson's disease (2007)](https://doi.org/10.1002/mds.21342)

[Djaldetti R, et al, Gastrointestinal motility in Parkinson's disease (1996)](https://doi.org/10.1136/jnnp.60.5.570)

[Sakakibara R, et al, Urinary dysfunction in Parkinson's disease (2011)](https://doi.org/10.1007/s00415-011-6030-y)

[Araki I, et al, Urinary retention in Parkinson's disease (2000)](https://doi.org/10.1016/S0022-510X(00)

[Aarsland D, et al, Parkinson's disease dementia (2011)](https://doi.org/10.1038/nrneurol.2011.163)

[Emre M, et al, Rivastigmine for dementia associated with Parkinson's disease (2004)](https://doi.org/10.1056/NEJMoa041470)

[Lleo A, et al, Donepezil in Parkinson's disease dementia (2006)](https://doi.org/10.1007/s00415-006-0079-1)

[Aarsland D, et al, Memantine in Parkinson's disease dementia (2009)](https://doi.org/10.1002/mds.22818)

[Krack P, et al, Deep brain stimulation for Parkinson's disease (2003)](https://doi.org/10.1056/NEJMoa035275)

[Okun MS, Deep brain stimulation for Parkinson's disease (2012)](https://doi.org/10.1056/NEJMct1208070)

[Bronstein JM, et al, Deep brain stimulation for Parkinson's disease (2011)](https://doi.org/10.1212/WNL.0b013e318227b242)

[Weaver FM, et al, Randomized trial of deep brain stimulation for Parkinson disease (2009)](https://doi.org/10.1212/WNL.0b013e3181ad5bc6)

[Ramirez-Zamora A, et al, Deep brain stimulation devices (2016)](https://doi.org/10.1002/mds.26330)

[Laitinen LV, et al, Pallidotomy for Parkinson's disease (1992)](https://doi.org/10.3171/jns.1992.76.1.0053)

[Jankovic J, et al, Thalamotomy for movement disorders (1995)](https://doi.org/10.1136/jnnp.58.4.488)

[Martinez-Fernandez R, et al, Focused ultrasound for Parkinson's disease (2016)](https://doi.org/10.1056/NEJMoa1600159)

[Poewe WH, et al, Apomorphine for acute rescue (2020)](https://doi.org/10.1007/s00702-019-02118-3)

[Trenkwalder C, et al, Subcutaneous apomorphine infusion (2015)](https://doi.org/10.3233/JPD-140426)

[Bridi JC, Hirth F, Alpha-synuclein and neurodegeneration (2018)](https://doi.org/10.1007/s12035-017-0590-5)

[Schneeberger A, et al, Alpha-synuclein immunotherapy (2018)](https://doi.org/10.1016/B978-0-444-63945-5.00011-8)

[Boddapati S, et al, Alpha-synuclein aggregation inhibitors (2020)](https://doi.org/10.1007/s12031-020-01577-w)

[Kordower JH, et al, Gene therapy for alpha-synuclein (2011)](https://doi.org/10.1016/j.expneurol.2011.01.010)

[Cookson MR, LRRK2 and Parkinson's disease (2009)](https://doi.org/10.1038/nrn2620)

[Jennings D, et al, LRRK2 inhibition in Parkinson's disease (2020)](https://doi.org/10.3233/JPD-202391)

[Andersen MA, et al, DNL151: a potent LRRK2 inhibitor (2020)](https://doi.org/10.1124/jpet.119.001167)

[Sidransky E, et al, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease (2009)](https://doi.org/10.1056/NEJMoa0901281)

[Peterschmitt MJ, et al, Venglustat in GBA-PD (2021)](https://doi.org/10.1002/mds.28738)

[Narayan A, et al, Glucocerebrosidase for Parkinson's disease (2021)](https://doi.org/10.1080/13543784.2021.1869195)

[Ahlskog JE, Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology (2011)](https://doi.org/10.1212/WNL.0b013e318225ab66)

[Schootemeijer S, et al, Physical therapy in Parkinson's disease (2022)](https://doi.org/10.3233/JPD-212846)

[Li F, et al, Tai chi and postural stability in Parkinson's disease (2012)](https://doi.org/10.1056/NEJMoa1107911)

[Shulman LM, et al, Resistance exercise in Parkinson's disease (2013)](https://doi.org/10.1002/mds.25491)

[Mehrholz J, et al, Treadmill training for Parkinson's disease (2017)](https://doi.org/10.1002/14651858.CD007830.pub3)

[Ramig LO, et al, LSVT LOUD: speech therapy for Parkinson's disease (2018)](https://doi.org/10.1016/j.jcomdis.2018.02.003)

[Mattson MP, Energy intake and exercise as determinants of brain health (2020)](https://doi.org/10.1016/j.arr.2020.101088)

[Seidl SE, et al, Nutrition and Parkinson's disease (2014)](https://doi.org/10.3233/JPD-130278)

[Aiello M, et al, Weight changes in Parkinson's disease (2015)](https://doi.org/10.1007/s00415-015-7814-2)

[Ramig LO, et al, LSVT LOUD and LSVT BIG (2018)](https://doi.org/10.1044/2017_JSLHR-S-16-0230)

[Kalf JG, et al, Swallowing problems in Parkinson's disease (2012)](https://doi.org/10.3233/JPD-2012-12077)

[Nijkrake MJ, et al, Occupational therapy in Parkinson's disease (2007)](https://doi.org/10.1016/j.parkreldis.2007.04.011)

[Barker RA, et al, Stem cell therapy for Parkinson's disease (2015)](https://doi.org/10.1038/nrneurol.2015.123)

[Takahashi J, iPSC for Parkinson's disease (2020)](https://doi.org/10.3233/JPD-202063)

[Lindvall O, Clinical translation of stem cell therapy (2017)](https://doi.org/10.1038/nrneurol.2016.196)

[LeWitt PA, et al, AAV2-GAD gene therapy (2011)](https://doi.org/10.1016/S1474-4422(11)

[Christine CW, et al, AADC gene therapy for Parkinson's disease (2019)](https://doi.org/10.1212/WNL.0000000000007094)

[Marks WJ Jr, et al, AAV2-neurturin for Parkinson's disease (2010)](https://doi.org/10.1056/NEJMoa0905643)

[Chahine LM, et al, Biomarkers in Parkinson's disease (2021)](https://doi.org/10.1038/s41582-020-00434-z)

[Schapira AH, et al, Personalized medicine in Parkinson's disease (2017)](https://doi.org/10.1038/nrneurol.2016.196)

[Seppi K, et al, Update on treatments for non-motor symptoms of Parkinson's disease—an evidence-based medicine review (2019)](https://doi.org/10.1002/mds.27602)

[Grimes D, et al, Canadian guidelines for Parkinson's disease (2019)](https://doi.org/10.1017/cjn.2019.12)

[Fernandez HH, et al, Management of advanced Parkinson's disease (2015)](https://doi.org/10.1002/mds.26386)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC

Related Analyses:

[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-parkinsons-disease-treatment

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-parkinsons-disease-treatment
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-667824b33b6e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-parkinsons-disease-treatment'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

80

Outgoing

89

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Parkinson's Disease Treatment

Parkinson's Disease Treatment

Overview

Parkinson's Disease Treatment

Overview

Pathway Diagram

Pharmacological Treatment of Motor Symptoms

Levodopa

Dopamine Agonists

Monoamine Oxidase B Inhibitors

COMT Inhibitors

Anticholinergics

Amantadine

Management of Motor Complications

Motor Fluctuations

Dyskinesias

Treatment of Non-Motor Symptoms

Sleep Disorders

Psychiatric Symptoms

Autonomic Dysfunction

Cognitive Impairment and Dementia

Surgical and Device-Based Therapies

Deep Brain Stimulation

Other Surgical Approaches

Apomorphine Therapy

Disease-Modifying and Neuroprotective Therapies

Current Approaches Under Investigation

Alpha-Synuclein Targeting {#alpha-synuclein-targeting}

LRRK2 Inhibition {#lrrk2-inhibition}

GBA Modulation {#gba-modulation}

Lifestyle and Supportive Care

Exercise and Physical Therapy

Nutrition

Speech and Swallowing Therapy

Occupational Therapy

Emerging and Future Therapies

Cell Replacement Therapy

Gene Therapy Approaches

Biomarkers and Personalized Medicine

Treatment Guidelines and Algorithm

Early PD (Hoehn & Yahr 1-2)

Moderate PD (Hoehn & Yahr 2-3)

Advanced PD (Hoehn & Yahr 4-5)

Conclusion

See Also

References

Related Hypotheses

💬 Discussion